StockNews.com upgrades Fortress Biotech (NASDAQ:FBIO) to “hold”


Fortress Biotech (NASDAQ:FBIO – Get a review) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report released Thursday.

A number of other research companies also weighed in on FBIO. Roth Capital reiterated a “buy” rating on Fortress Biotech shares in a Tuesday, March 29 research note. TheStreet downgraded shares of Fortress Biotech from a “c-” rating to a “d+” rating in a Monday, February 14 research note. Zacks Investment Research upgraded shares of Fortress Biotech from a “strong sell” rating to a “hold” rating in a Friday, May 13 report. Finally, Cantor Fitzgerald reissued a “buy” rating and posted a $6.00 price target on Fortress Biotech shares in a Friday, May 13 report. Two investment analysts gave the stock a hold rating and five gave the company a buy rating. According to MarketBeat.com, Fortress Biotech currently has a consensus rating of “Buy” and a consensus target price of $9.50.

Fortress Biotech stock opened at $0.87 on Thursday. Fortress Biotech has a 1-year minimum of $0.79 and a 1-year maximum of $4.49. The company has a market capitalization of $93.66 million, a price-earnings ratio of -1.01 and a beta of 2.27. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt ratio of 0.46. The company has a 50-day simple moving average of $1.19 and a 200-day simple moving average of $2.00.

Fortress Biotech (NASDAQ:FBIO – Get Rating) last released its quarterly earnings data on Thursday, May 12. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating analyst consensus estimates of ($0.28) by $0.10. Fortress Biotech had a negative net margin of 88.31% and a negative return on equity of 32.56%. During the same period last year, the company posted ($0.11) earnings per share. On average, equity research analysts expect Fortress Biotech to post -0.88 EPS for the current year.

A number of large investors have recently changed their positions in FBIO. Advisor Group Holdings Inc. increased its equity stake in Fortress Biotech by 113.0% during the 1st quarter. Advisor Group Holdings Inc. now owns 20,020 shares of the biopharmaceutical company worth $27,000 after acquiring 10,620 additional shares in the last quarter. Citigroup Inc. increased its equity stake in Fortress Biotech by 160.5% during the third quarter. Citigroup Inc. now owns 8,879 shares of the biopharmaceutical company worth $29,000 after acquiring 5,470 additional shares in the last quarter. Marshall Wace LLP purchased a new stake in Fortress Biotech stock during Q4 for $30,000. Two Sigma Securities LLC purchased a new stake in Fortress Biotech stock during Q3 for $33,000. Finally, Envestnet Asset Management Inc. purchased a new equity stake in Fortress Biotech during Q1 for $33,000. 30.92% of the shares are held by hedge funds and other institutional investors.

About Fortress Biotech (Get a rating)

Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of moderate to severe non-nodular acne vulgaris; Targadox for severe acne; Exelderm cream for symptoms of ringworm and jock itch; Ceracade for dry skin; Luxamend for dressing and treating wounds; and Accutane capsules for severe recalcitrant nodular acne.

Featured Articles

Analyst Recommendations for Fortress Biotech (NASDAQ: FBIO)



Get news and reviews for Fortress Biotech Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fortress Biotech and related companies with MarketBeat.com’s free daily email newsletter.

About Sally Dominguez

Check Also

“My acne was so bad that I stopped having sex – but now I’ve found a natural cure”

Mandy Nazé, 29, says her face, forehead, chest, neck and back were badly affected and …